daytrading may 30 afternoon, page-63

Great ann by VHL:
Virax Completes Acquisition of US Specialty Oncology
Company and Novel Cancer Drug Candidate
HIGHLIGHTS
? Pathway Oncology acquisition finalised with Virax taking exclusive worldwide license to valuable drug candidate GGTI-2418
? Virax becomes mid-clinical stage oncology company, with Phase 2 clinical program expected 2015/16
? Overwhelming shareholder support for all scrip acquisition to be paid in three tranches
? High calibre international biotechnology executive Paul Hopper joins board as executive director